Background: Liver cancer is the fifth cause of cancer-related deaths in Japan. The BioBank Japan (BBJ) project included 200,000 patients with 47 diseases and samples; their clinical information can be used for further studies. Methods: Patients diagnosed with liver cancer (n ¼ 1733; 1316 men, 417 women) were included. Histology, patient characteristics, clinical characteristics, and causes of death were collected. Cumulative and relative survival rates for liver cancer were calculated. Results: Of the 1354 patients with available liver cancer histology, 91.9% had hepatocellular carcinoma (HCC). Compared with the National Health and Nutrition Examination Survey, greater proportions of the male patients in this cohort were daily alcohol consumers (26%), and a greater proportion of the men was overweight/obesity (22%). Although Japan is the only Asian country with a predominance of hepatitis C virus (HCV)-related HCC, the prevalence of HCV infection (44%) was lower than that in a previous study. The 3-, 5-, and 10-year cumulative survival rates were 57%, 47%, and 25% in men, respectively, and 49%, 41%, and 27% in women, respectively. Conclusions: The present results provide an overview of the patients with liver cancer in the BBJ project. We are planning further analyses combined with various high-throughput 'omics' technologies. accounting for approximately 70% of cases of HCC. However, the importance of the chronic liver diseases nonalcoholic fatty liver
Introduction
Liver cancer is the second leading cause of death worldwide, accounting for 745,000 deaths in 2012, 1 and the fifth cause of cancerrelated deaths in Japan. 2 According to the Japanese National vital statistics, a total of 40,099 persons (19,208 men and 20,891 women) died of liver cancer in 2014. 2 Also, data from the population-based cancer registries in Japan indicate that 43,677 persons (28,623 men and 15,054 women) were diagnosed with liver cancer in 2012. 3 The most prevalent type of primary liver cancer is hepatocellular carcinoma (HCC), 4 accounting for 94% of liver cancers in Japan. 5 Although hepatitis B viral (HBV) infection is a predominant cause of HCC in many Asian countries such as China, South Korea, Singapore, Thailand, Malaysia, India, the Philippines, and Taiwan, the main cause of HCC in Japan is hepatitis C viral (HCV) infection, 6 accounting for approximately 70% of cases of HCC. However, the importance of the chronic liver diseases nonalcoholic fatty liver disease (NAFLD) and nonalcoholic liver steatohepatitis (NASH) as risk factors for HCC has recently increased. 7 The BioBank Japan (BBJ) project is a large patient-oriented cohort consisting of more than 200,000 patients with 51 diseases, and DNA and serum samples and clinical information can be used for further studies. In this report, we aimed to provide an overview of the patients with liver cancer in the BBJ project.
Materials and methods

Study population
The 
Data collection
Information about smoking habits (never, former, current smoker of <20 pack years, current smoker of 20 pack years, current smoker of unknown pack years, or unknown), alcohol consumption habits (never, former, current drinker of <15 g/day, current drinker of 15e29 g/day, current drinker of 30 g/day, or unknown), height, weight, physical activity frequency (none, 1e2 times/week, 3 times/week, or unknown), family history of liver cancer (yes, no/unknown), and medical history of HBV or HCV infection (yes, no/unknown) was obtained through medical records and interviews using a standardized questionnaire at the time of enrollment.
9e12 Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters and categorized as <18.5 kg/m 2 , 18.5e24.9 kg/m 2 , 25.0e29.9 kg/m 2 , 30 kg/ m 2 , or unknown. Birth year; sex; time to entry in this cohort, from the diagnosis of liver cancer; age at entry in this cohort; liver cancer histology; laboratory examinations such as blood chemical markers including serum carcinoembryonic antigen (CEA; <5 ng/mL, 5e9 ng/mL, 10 ng/mL, or unknown), carbohydrate antigen 19-9 (CA 19-9; <37 U/mL, 37e99 U/mL, 100 U/mL, or unknown), and alphafetoprotein (AFP; <10 U/mL, 10e99 U/mL, 100 U/mL, or unknown) levels; and imaging data were collected from medical records. Liver cancer histology was based on tissue obtained at biopsy or cytological samples, and missing data for histological types were complemented by data from tissue samples. Liver cancer stage was categorized according to the Japanese Classification of Liver Cancer, the Fourth (2000) and Fifth (2008) Editions (stage I, II, III, IV, or unknown). Pathologic stage was primarily used for classification, and missing data for pathologic stage were complemented with clinical stage results.
Follow-up
The follow-up survival survey was implemented from 2010 to 2014 to collect patient vital status, and the data were coded according to the 10th revision of the International Classification of Disease.
Statistical analysis
Sex-specific statistical analyses were conducted. First, we described the distribution of time from the initial diagnosis of prostate cancer to entry into the study cohort. Second, we drew an age-specific distribution of the patients with liver cancer and compared that with the Patient Survey in Japan, 2005. 13 Ministry of Health, Labor and Welfare, Japan. The relative survival rates were calculated by dividing the cumulative survival rates by age-adjusted expected survival rates. All statistical analyses were performed using SAS software (version 9.4; SAS Institute Inc., Cary, NC, USA).
Results
The distribution of time from the initial diagnosis of liver cancer to entry into the study cohort is displayed in Fig. 1 . The proportion of patients who enrolled <1, 1, and 2 years after the initial diagnosis of liver cancer were 34.6%, 21.1%, 11.1%, and 33.2% in men and 34.1%, 22.1%, 14.4%, and 29.4% in women, respectively. The mean ± standard deviation age of the patients was 68.0 ± 8.5 (range, 32e92) years (Fig. 2) . Patients in this study appeared to be slightly younger than patients in the national survey in Japan. 13 Of the 1354 patients with information on the histology of liver cancer, 91.9% had HCC, and 3.7% had intrahepatic cholangiocarcinoma ( Table 1 ). Of all the included patients, 20.1% of men and 25.6% of women were obese; 31.4% of men and 9.1% of women were current alcohol drinkers; 25.6% of men and 8.4% of women were current smokers; and 79.1% of men a b Fig. 2 . Age-specific distribution of the patients with liver cancer for men (a) and women (b). Table 3 shows the causes of death due to liver cancer among the patients who entered the cohort 90 days from the diagnosis of liver cancer. The mortality rate during the study period was about 75% for men and 73% for women. Cancer-related mortality occurred for 65% of the men and 68% of the women who died, and the remaining patients died because of hepatic failure (0.5% of men), rupture of esophageal varices (0.5% of men), or other reasons. The 3-, 5-, and 10-year cumulative survival rates were 57%, 47%, and 25% in men, respectively, and 49%, 41%, and 27% in women, respectively (Fig. 3) . The 5-and 10-year relative survival rates were 53% and 34% in men, respectively, and 47% and 38% in women, respectively.
Discussion
The results of the present study provide an overview of the patients with liver cancer in the BBJ project, which is a large patient-based biobank. A strength of this cohort study is its prospective design with a large number of patients who were recruited from hospitals located nationwide in Japan.
The histology of liver cancer was not available for 61% of the patients because current guidelines for liver cancer from the Japan Society of Hepatology 15 indicate that only the use of imaging results in an accurate diagnosis of HCC. The most prevalent type (91.9%) of primary liver cancer was HCC, similar to the reported 94% in Japan. 5 Therefore, HCC might have been present
for a large proportion of the patients without identified histology. Japan is the only Asian country with a predominance of HCVrelated HCC 6 ; approximately 70% and 16% of HCC cases were caused by HCV and HBV infection, respectively. In our analysis, 44% and 12% of men and 53% and 8% of women had a medical history of HCV and HBV infection, respectively. The lower prevalence of HBV or HCV intention might have resulted from misclassification because we obtained the medical history of HCV/HBV infection only when the patients experienced. There are several risk factors for liver cancer other than infections, such as NASH, which is associated with obesity, 16 habitual alcohol consumption, 17 and smoking. 18 According to the National Health and Nutrition Examination Survey in Japan, 19 28% of men and 22% of women are obese (BMI 25.0 kg/ m 2 ), 5% of men and 9% of women reportedly currently drink alcohol, and 47% of men and 11% of women are current smokers. Compared with the National Health and Nutrition Examination Survey, a greater proportion of the male patients in the present study were daily alcohol consumers, and a greater proportion of women was overweight/obesity. Since the number of people with HCV infection is gradually decreasing in Japan, 20 these lifestyle choices might have resulted in the lower prevalence of HBV and HCV infections. The Japanese Association of Clinical Cancer Centers reported that the 5-and 10-year relative survival rates for liver cancer were 34.8% and 15.3%, respectively. 21 The relative survival rates in the present study were much higher. However, because the data regarding factors that affect survival rate, such as stage, surgery, 22e24 or chemotherapy 25, 26 were missing, the results may have been biased. 
Conclusion
The present study provides an overview of the patients with liver cancer in the BBJ project. We are planning further analyses combined with various high-throughput 'omics' technologies using DNA and serum samples from the BBJ project. However, the interpretation of the forthcoming results may require careful consideration because of the missing data of not only newly diagnosed cases but also prevalent cases.
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